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Abstract: Phosphodiesterases (PDEs) are important enzymes that hydrolyze the cyclic 
nucleotides adenosine 3′5′-cyclic monophosphate (cAMP) and guanosine 3′5′-cyclic mono-
phosphate (cGMP) to their inactive 5′ monophosphates. They are highly conserved across 
species and as well as their role in signal termination, they also have a vital role in intra-cellular 
localization of cyclic nucleotide signaling and integration of the cyclic nucleotide pathways with 
other signaling pathways. Because of their pivotal role in intracellular signaling, they are now 
of considerable interest as therapeutic targets in a wide variety diseases, including COPD where 
PDE inhibitors may have bronchodilator, anti-inﬂ  ammatory and pulmonary vasodilator actions.
This review examines the diversity and cellular localization of the isoforms of PDE, the known 
and speculative relevance of this to the treatment of COPD, and the range of PDE inhibitors in 
development together with a discussion of their possible role in treating COPD.
Keywords: COPD, phosphodiesterase, bronchodilator, anti-inflammatory, pulmonary 
vasodilator
Cyclic nucleotide signaling
cAMP was the ﬁ  rst “second messenger” to be identiﬁ  ed (Sutherland 1970; Beavo 
and Brunton 2002). It is now known that it transduces the intracellular effects of 
many hormones and neurotransmitters (Habener 2001) and some of the effects of 
T-cell receptor activation (Ledbetter et al 1986). The level of intracellular cAMP is 
regulated by the balance of activity between adenyl cyclase (AC), which is responsible 
for its formation and cyclic nucleotide phosphodiesterase which is responsible for its 
inactivation. cAMP exerts its effects through activation of protein kinase A (PKA), 
the GTP-exchange protein EPAC and via cAMP gated ion channels in the cell mem-
brane. Changes in cAMP levels can be extremely short lived, as in the rapid and brief 
rise in cAMP levels seen over milliseconds in olfactory neurons (Breer, 1993) or more 
sustained, for example the changes over hours seen in the effects of LHRH on anterior 
pituitary cells (Borgeat et al 1972).
Cyclic nucleotides, particularly cyclic AMP, have important regulatory roles 
in virtually all cell types involved in the pathophysiology of COPD. Elevation of 
intracellular cAMP levels suppresses the activity of immune and inﬂ  ammatory cells 
(Bourne et al 1974; Kammer 1988; Moore and Willoughby 1995) and elevation 
of both cAMP and cGMP leads to smooth muscle relaxation. cAMP may have an 
additional role in modulating airway smooth muscle hypertrophy and hyperplasia as 
it has cytostatic effects in many cell types (Pastan et al 1975; Friedman et al 1976), 
and exerts an inhibitory effect inﬂ  uence on airway smooth muscle proliferation (Lew 
et al 1992; Tomlinson et al 1995).
In most cells and tissues, the capacity for hydrolysis of cyclic nucleotides by PDEs 
is an order of magnitude greater than the maximum rate of synthesis of cAMP and 
cGMP and thus small reductions in the activity of PDEs can produce large increases in International Journal of COPD 2008:3(4) 544
Halpin
the level of cyclic nucleotides and signiﬁ  cant changes in the 
activity of cAMP-dependent protein kinase. There is growing 
evidence for sub-cellular compartmentalization of cAMP 
levels, allowing control of cAMP dependent signal transduc-
tion both spatially and temporally and PDE plays a crucial 
role in this sub-cellular localization by creating boundaries 
for cAMP diffusion (Mongillo et al 2004) and its role is more 
than simply a mechanism of terminating the signal.
This sub-cellular compartmentalization has been shown 
to be important in cardiac myocytes but its role in inﬂ  amma-
tory cells and airway smooth muscle is still unclear.
PDE isoforms
Shortly after the identiﬁ  cation of PDE it was realized that 
there was more than one isoform. PDEs with different 
chromatographic and kinetic properties, different substrate 
speciﬁ  city and pharmacological properties were identiﬁ  ed 
in extracts from brain and other tissues (Thompson and 
Appleman 1971). It is now realized that PDE forms a super 
family of enzymes containing at least eleven families. Three 
catalytic domains can hydrolyze the 3′ phosphate bond of 
cyclic nucleotides: the class I domain is shared by protozoa 
and metazoa, the class II domain is found in fungi, slime 
mould and amoebae and the class III domain has only been 
identiﬁ  ed in the slime mould Dictostelium discoideum.
The catalytic domain in metazoa is highly conserved 
and is characterized by the metal binding domain 
H(X)3H(X)25–35(D/E), where H is histidine, D is aspartic 
acid, E is glutamic acid and X can be any amino acid. This 
domain is shared by a large superfamily of metal-dependent 
phosphohydrolases known as the HD-family and indicates 
that divalent cations are involved in cyclic nucleotide hydro-
lysis. Although PDEs are related to this superfamily they are 
distinct and have other conserved regions which they share 
with each other (Aravind and Koonin 1998).
Analysis of the human genome has identiﬁ  ed 21 genes 
for cyclic nucleotide PDEs and the physiochemical and 
regulatory properties of the proteins they code for have 
been characterized (Conti and Jin 1999; Soderling and 
Beavo 2000; Francis et al 2001). Based on their molecular 
sequence, kinetics, regulation and pharmacological charac-
teristics mammalian PDEs can be classiﬁ  ed into 11 families, 
denoted by an Arabic numeral 1–11. Some of these families 
have more than one member each of which is encoded by 
different genes and these are denoted by a capital letter after 
the numeral, eg, PDE4A, PDE4B, PDE4C, and PDE4D. To 
complicate matters further, most of the genes encoding PDEs 
have multiple promoters and the transcripts are subject to 
alternate splicing, resulting in nearly one hundred different 
PDE open reading frames (Conti and Beavo 2007). The 
splicing variant is denoted by a ﬁ  nal Arabic numeral after 
the letter, eg, PDE4D3.
All PDEs contain three functional domains: a conserved 
catalytic core, a regulatory N-terminus and the C-terminus 
(Thompson 1991; Bolger 1994; Conti and Beavo 2007). The 
carboxyl terminus is similar in all the PDE families except 
PDE6, with 18%–46% sequence identity overall. Although 
there is some evidence that the C-terminal region of PDE4 
may be involved in dimerization (Kovala et al 1997) and may 
also be a target for regulatory phosphorylation (Lenhard et al 
1996) its physiological function remains unclear.
The N-terminal domain shows great diversity between 
PDE families (Figure 1) and understanding the functional 
relevance of the differences in the N-terminal domains is 
crucial to understanding the regulation and sub-cellular 
localization of different PDEs and to the development of 
drugs that modulate PDE activity.
There are domains that are essential for ligand binding, 
PDE oligomerization domains and kinase recognition and 
phosphorylation domains which regulate PDE function. The 
regulatory domains include the calmodulin binding domain 
found in PDE1, the cGMP binding (GAF) domains found 
in PDE2, 5, 6, 10, and 11, and the so called upstream con-
served regions 1 and 2 (UCR1 and UCR2) found in PDE4. 
The N-terminal domains also contain regions that determine 
intracellular localization.
The catalytic domain which contains about 270 amino 
acids shows a high degree (25%–49%) of amino acid conser-
vation between the 11 PDE families; however, the families 
themselves and the isoforms within the respective family 
have varying substrate preferences for cAMP and cGMP. In 
mammals PDE4, PDE7 and PDE8 hydrolyze cAMP selec-
tively, PDE5, PDE6, and PDE9 hydrolyse cGMP selectively 
and the remaining ﬁ  ve PDEs (PDE1, 2, 3, 10, and 11) hydro-
lyze both cAMP and cGMP. Current evidence suggests that 
substrate speciﬁ  city is conferred by the orientation of a single 
glutamine residue within the catalytic site which can either 
form hydrogen bonds with cAMP, cGMP or both depending 
on its ﬁ  xed orientation or ability to rotate (Zhang et al 2004). 
The catalytic region comprises 17 α-helices divided into 
three subdomains (Xu et al 2000; Jeon et al 2005). There 
is an N-terminal cyclin-fold region, a linker region and a 
C-terminal helical bundle. The three sub-domains form a 
deep hydrophobic pocket and this contains four subsites: 
a metal-binding site (M site), a core pocket (Q pocket), 
a hydrophobic pocket (H pocket) and a lid region (L region) International Journal of COPD 2008:3(4) 545
ABCD of the phosphodiesterase family
(Sung et al 2003; Jeon et al 2005). As discussed above, it 
appears that at least one of the metals binding at the M site 
which lies at bottom of the pocket is zinc and the other is 
likely to be magnesium.
It appears likely that PDEs function as dimers or oligomers 
in most cells and dimerization is an essential structural 
element that determines the regulatory properties and inhibitor 
sensitivities of PDE4 as discussed below (Richter and Conti 
2004). The spatial location of PDEs within cells is now also 
known to be important in determining their intracellular 
effects and this appears to be determined to some extent by 
the presence of different targeting domains in the N-terminal 
domain. One explanation for the multiple isoforms is targeting 
in different sub-cellular locations (Figure 2).
Scaffolding molecules such as A-kinase anchoring 
proteins (AKAP) dynamically assemble cAMP effector 
molecules, such as PKA, and PDEs into signaling complexes 
which regulate the temporal and spatial effects of cAMP 
(McConnachie et al 2006). In particular PDE4D3 and PKA 
have been shown to be associated with muscle mAKAP and 
phosphorylation of PDE4D3 by PKA in these complexes 
enhances its PDE activity thus forming a negative feedback 
control system to limit the activation of PKA and regulate 
local cAMP concentrations (Dodge et al 2001). Under 
resting conditions PDE4D3 maintains local cAMP concen-
trations below the threshold required for PKA activation 
and when cAMP levels rise following receptor stimulation, 
phosphorylation of PDE4D3 by activated PKA increases its 
activity returning cAMP levels to baseline (Dodge-Kafka 
et al 2005).
In some situations PDEs themselves may function as 
scaffolding for the assembly of macromolecular complexes 
which compartmentalize the effects of cAMP. PDE4D3 
interacts with EPAC (a guanine nucleotide exchange fac-
tor for the Ras-like small GTPases Rap1 and Rap2 (Bos 
2003)) and ERK5 (extracellular signal regulated kinase 
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Figure 1 Schematic diagram of the domain structure of the eleven PDE families. Copyright © 2007. Adapted from with permission Conti M, Beavo J. 2007. Biochemistry and 
physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem, 76:481–511. International Journal of COPD 2008:3(4) 546
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Figure 2 Schematic representation of the some of the complexes in which phosphodiesterases (PDEs) are involved in a hypothetical cell. Reprinted from with permission 
Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem, 76:481–511. 
Copyright © 2007.   Annual Reviews www.annualreviews.org.
Abbreviations: AC, adenylyl cyclase; AKAP, A kinase – anchoring proteins; βAR, arrestins; βAR2, adrenergic receptor 2; CFTR, cystic ﬁ  brosis transmembrane conductance 
regulator; CNGC, cyclic nucleotide gated channels; mit, mitochondria; PKA, protein kinase A; RyR, ryanodine receptors.International Journal of COPD 2008:3(4) 547
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(Zhou et al 1995)). These intermolecular interactions 
facilitate the dissemination of distinct cAMP signals 
through each effector protein. ERK phosphorylation of 
PDE4D3 decreases the phosphodiesterase activity, thereby 
favoring local accumulation of cAMP and subsequent 
EPAC activation (Dodge-Kafka et al 2005).
PDE4 also forms another macromolecular signaling com-
plex with β-arrestin to regulate cAMPs diffusion from activated 
receptors. Arrestins bind speciﬁ  cally to active ( phosphorylated) 
G-protein coupled receptors (GPCRs), and arrest or reduce sig-
naling by these receptors. β-arrestin binds to the β-adrenergic 
receptor G-protein and recruits PDE4. This both regulates 
local levels of cAMP and also controls phosphorylation of the 
β-receptor switching its predominant coupling from stimulatory 
guanine nucleotide regulatory protein (Gs) to inhibitory guanine 
nucleotide regulatory protein (Gi) thus controlling PKA activity 
at the membrane (Baillie et al 2003).
PDE isoforms and COPD
Most interest in PDE isoforms from the perspective of COPD 
has centered on the PDE4 family, but PDE1, PDE3, PDE5, 
and PDE7 may also be of interest as therapeutic targets in 
COPD. This reﬂ  ects the fact that COPD is now recognized 
as an inﬂ  ammatory disease with pulmonary and systemic 
components (National Institute for Clinical Excellence 
[NICE] 2004; Global Initiative for Chronic Obstructive 
Pulmonary Disease).
Tobacco smoke induces an inﬂ  ammatory response in the 
lungs that leads to the development of airﬂ  ow obstruction, 
mucus hypersecretion, parenchymal destruction and systemic 
effects. There is inﬂ  ammation in the conducting airways, the 
parenchyma and in the pulmonary vasculature, and increased 
levels of inﬂ  ammatory mediators in peripheral blood. As 
the disease progresses small airways become occluded by 
inﬂ  ammatory exudates containing mucus (Hogg et al 2004) 
and lung parenchymal tissue is destroyed. The systemic 
effects include skeletal muscle dysfunction, nutritional abnor-
malities and weight loss, cardiovascular, CNS and skeletal 
effects (Agusti et al 2003; Wouters 2002; Halpin, 2007).
The inﬂ  ammation in COPD involves cytotoxic (CD8+) 
T cells, macrophages and neutrophils, and inﬂ  ammatory 
mediators, including cytokines, chemokines, proteinases 
and oxidants. CD8+ T cells and macrophages inﬁ  ltrate 
airway tissues while neutrophils are the predominant cells 
recovered from the airway lumen (O’Shaughnessy et al 
1997; Saetta et al 1999). The inflammatory mediators 
and proteolytic enzymes released from these cells lead 
to mucus-hypersecretion in large airways, progressive 
obstructive changes in the small airways and destruction 
of lung parenchyma (Jeffery 2001a, b; Agostini et al 2003). 
Eosinophils may also play a role during exacerbations 
(Saetta et al 1994) and mast cells may also be important as 
they have been found in increased numbers in the airway 
of smokers with bronchitis and airﬂ  ow limitation (Grashoff 
et al 1997). Recently, dendritic cells have also been shown 
to be important in the inﬂ  ammatory process in COPD 
(Tsoumakidou et al 2008). Structural cells, such as epithelial 
cells, ﬁ  broblasts and airway smooth muscle cells are also 
thought to be important and have been shown to release 
inﬂ  ammatory mediators, such as interleukin (IL)-8, tumor 
necrosis factor (TNF)-α, IL-10 and transforming growth 
factor (TGF)-β (Saetta et al 2001; Jeffery 2001b) which can 
lead to subepithelial and peribronchiolar ﬁ  brosis (Lee et al 
2001). These cells also express adhesion molecules which 
modulate interactions with lymphocytes and recruitment of 
neutrophils into the airway lumen.
PDE4 is the major regulator of cAMP levels in leukocytes 
and other inﬂ  ammatory cells (Barnette 1999). Inhibition of 
PDE4 increases intracellular cAMP concentrations which 
ultimately results in reduction of cellular inﬂ  ammatory 
activity. Targeted inhibition of PDE4 has been considered 
as a way of reducing inﬂ  ammation in patients with asthma 
or COPD (Barnette 1999; Compton et al 2001).
PDE3 is present in T lymphocytes, macrophages, mono-
cytes as well as in airway smooth muscle and endothelial 
cells (Schudt et al 1995; Torphy 1998). Thus, in theory, 
inhibitors of PDE3 could act both as bronchodilators and 
anti-inﬂ  ammatory drugs and may have synergistic effects 
with PDE4 inhibitors.
PDE1 accounts for more than 35% of the cyclic nucleo-
tide hydrolytic activity in human airway smooth muscle 
(Torphy et al 1993) and it has been implicated in human 
vascular smooth muscle proliferation (Rybalkin et al 1997; 
Rybalkin et al 2002a). It is not known whether or not it is 
also involved in airway smooth muscle proliferation but if 
it is, inhibitors of PDE1 could be of considerable beneﬁ  t in 
treating airway remodeling in COPD.
PDE5 is also expressed in pulmonary vascular smooth 
muscle and airway smooth muscle (Yanaka et al 1998; Sebkhi 
et al 2003) and has a pivotal role in controlling regulation of 
smooth muscle tone by nitric oxide (NO), atrial natriuretic 
peptide (ANP), and other endogenous vasodilators. Inhibition 
of PDE5 in patients with COPD has the potential to reduce 
pulmonary vascular resistance and prevent vascular remod-
eling, as well as causing bronchodilatation and it may also 
have anti-inﬂ  ammatory actions.International Journal of COPD 2008:3(4) 548
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Finally, an isoform of PDE7 is also abundantly expressed 
in the airway smooth muscle, and in many pro-inﬂ  ammatory 
and immune cells, including neutrophils recovered from 
induced sputum in patients with COPD. Theoretically inhibi-
tion of PDE7 may have an anti-inﬂ  ammatory effect but so 
far this has not been demonstrated, although inhibition of 
PDE7 may augment the anti-inﬂ  ammatory effects of PDE4 
inhibition (Smith et al 2004)
The structural and functional characteristics of these 
phosphodiesterase, as well as drugs which affect their activity 
will now be considered from the perspective of understanding 
their role and potential as therapeutic targets in COPD.
PDE4 isoforms
More than 20 isoforms of PDE4 are known at present. They 
are found in many cell types in the lung including airway 
epithelial cells (Dent et al 1998), airway and pulmonary 
vascular smooth muscle (de Boer et al 1992; Pauvert et al 
2002; Rabe et al 1993), and pulmonary vascular endo-
thelium (Thompson et al 2002). They are also present 
in T lymphocytes (Tenor et al 1995; Giembycz et al 1996), 
neutrophils (Nielson et al 1990), monocytes (Seldon et al 
1995), eosinophils (Dent et al 1994), and basophils (Peachell 
et al 1992). Their function has been explored by the use of 
selective inhibitors and genetic manipulations including 
targeted gene knockout. The PDE4 isoforms have closely 
related kinetic properties and are all inhibited by rolipram.
Four human PDE4 subtypes (A, B, C, and D) have 
identiﬁ  ed. The genes for these enzymes have been cloned 
and expressed. PDE4A and PDE4C are located on human 
chromosome 19 at 19p13.2 and 19p13.11, PDE4B is on 
chromosome 1p31 and PDE4D is on chromosome 5q12 
(Bolger et al 1993; McLaughlin et al 1993; Milatovich et al 
1994; Engels et al 1995; Horton et al 1995; Szpirer et al 
1995; Nemoz et al 1996). The N-terminal domain of most 
members of the PDE4 family contains the two upstream 
conserved regions UCR1 and UCR2 mentioned above; 
however several truncated variants of PDE4B and PDE4D 
are formed via alternate splicing resulting in deletions of part 
or all of UCR1 (Figure 3). The PDE4 isoforms can thus be 
divided into three groups on the basis of the structure of the 
N-terminal domain. Long isoforms contain both UCR1 and 
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Figure 3 Schematic representation of human PDE4 subtypes and products of mRNA splice variants The number of amino acid (AA) residues in each protein appears to the 
right of the schematic diagram. Adapted and updated with permission from Torphy TJ. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J 
Respir Crit Care Med, 157:351–70. Copyright © 2008 American Thoracic Society.
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UCR2, short isoforms lack UCR1, and supershort isoforms 
lack UCR1 and have a truncated UCR2. UCR1 contains a 
PKA phosphorylation site which allows long forms to be 
activated by this enzyme (Sette and Conti 1996; MacKenzie 
et al 2002), leading to local regulation of cAMP levels. All 
isoforms of PDE4 can be phosphorylated by ERK, but the 
effects of this on PDE4 activity depend on the presence of 
UCR1. Long isoforms are inhibited by ERK phosphorylation 
whereas short isoforms are activated and no effect on activity 
is seen in super short isoforms (MacKenzie et al 2000). 
There are signiﬁ  cant differences in the tissue distribution of 
the mRNA for the PDE4 isoforms (Table 1). PDE4A message 
is widely distributed in many tissues including pulmonary 
and inﬂ  ammatory cells (Engels et al 1994). PDE4C is absent 
from circulating inﬂ  ammatory cells and there are conﬂ  ict-
ing reports about the distribution of PDE4B in some tissues 
(eg, liver, kidney or pancreas) (McLaughlin et al 1993, 
Engels et al 1994) but general agreement that it is present in 
lung and inﬂ  ammatory cells. PDE4D is present in some but 
not all inﬂ  ammatory cells.
There is also evidence that the isoforms of PDE4 change 
as cells differentiate, suggesting that they are not simply 
redundant but have different intracellular roles. For example, 
differentiation of monocytes to macrophages is associated 
with a marked downregulation of PDE4D3 and PDE4D5, 
upregulation of PDE4B2 and induction of the PDE4A10 
long isoform (Shepherd et al 2004). Changes in isoforms 
may occur in disease and it has been reported that PDE4A4B 
is upregulated in macrophages from smokers with COPD 
(Barber et al 2004). In addition to their effect on enzyme 
activity the UCR domains are involved in interactions 
between PDE4 and scaffolding molecules such as myo-
megalin which localize components of the cAMP-dependent 
pathway to the Golgi/centrosomal region of the cell (Verde 
et al 2001). Deletions in the N-terminal domain affect subcel-
lular localization (Beard et al 2002). For example, PDE4A1 is 
exclusively membrane-associated and is normally localized 
to the Golgi (Shakur et al 1995; Pooley et al 1997), but dele-
tion of its unique N-terminal region of made it fully soluble 
and changed its location to the cytosol (Shakur et al 1993). 
The N-terminal domains of PDE4 isoforms also determine 
the ability of the enzyme to interact with other regulatory 
molecules such as the immunophilin XAP2 (Bolger et al 
2003) and to recruit other proteins to form signaling cascades. 
For example, PED4A5 can bind to the SH3 domains which 
are found in a variety of cytoplasmic tyrosyl protein kinases 
as well as in cytoskeletal and adaptor proteins (O’Connell 
et al 1996). The physiological signiﬁ  cance of these interac-
tions remains uncertain but they clearly demonstrate the 
complexity of intracellular signaling with cross-talk between 
different signaling cascades. An example of the importance 
of subcellular localization of PDE4 isoforms is their loca-
tion in airway epithelial cells where it has been shown that 
they conﬁ  ne cAMP generated by apical adenosine A2B 
receptors to a microdomain that includes the target CFTR 
channels and prevents a rise in total cellular cAMP levels 
(Barnes et al 2005). Furthermore, there is now evidence that 
although PDE4D is crucial in controlling the intracellular 
cAMP gradients and microdomains generated by stimula-
tion of both the β1 and β2 adrenergic receptors, the PDE4D5 
isoform is involved with β2 adrenergic receptor signaling and 
the PDE4D8 and PDE4D9 isoforms are associated with β1 
adrenergic receptor signaling (Richter et al 2008).
Binding of inhibitors to PDE4 is also inﬂ  uenced by the 
N-terminal domain structure. The binding kinetics of rolipram 
suggest that there two binding sites: a high afﬁ  nity site 
(HPDE4) with a Ki approximately 50–1000 times greater than 
binding to the low afﬁ  nity site (LPDE4). Deletion of the termi-
nal 332 amino acids prevents high afﬁ  nity binding of rolipram 
but has minimal effect on PDE4 catalytic activity. High afﬁ  nity 
binding predominates in the CNS, while low afﬁ  nity binding 
predominates in inﬂ  ammatory cells leading to important clini-
cal differences in the pharmacological properties of inhibitors. 
It was thought that high afﬁ  nity binding was associated with 
unwanted CNS and gastric side effects of inhibitors and that 
Table 1 Summary of the RT-PCR results with different human 
tissues and deﬁ  ned cell populations (After Engels et al 1994)
hPDE4A hPDE4B hPDE4C hPDE4D
Brain ++ ++ ++ ++
Liver ++ ++ (−)a ++ ++
Lung ++ ++ ++ ++
Trachea ++ ++ ++ ++
Kidney ++ ++ (−)a ++ ++
Placenta ++ ++ (−)a ++ ++
Heart ++ ++ ++ ++
Blood ++ ++ − ++
Promonocyte like1 ++ ++ − ++
T like cells2 ++ − − −
B like cells3 ++ ++ − −
Promyelocytic cells4 ++ ++ −
Neutrophils ± ++ − ±
Eosinophils ++ ++ − ++
++, expression; +, very weak expression;-, no expression; 1U937 cells; 2Jurkat cells; 
3Namalwa cells; 4peripheral blood promyelocytic HL-60 cells. adata from McLaughlin 
et al (1993).International Journal of COPD 2008:3(4) 550
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low afﬁ  nity binding was associated with the therapeutic effects 
of inhibitors (Torphy 1998; Jeon et al 2005); however, this has 
subsequently proved to be too simplistic (Houslay et al 2005) 
and cilomilast, which is a second generation inhibitor which 
targets low afﬁ  nity binding, still produces adverse effects 
including emesis (Torphy et al 1999).
Cilomilast and roﬂ  umilast are the most well character-
ized second generation PDE4 inhibitors but their clinical 
utility is still inﬂ  uenced by the fact that administration at 
therapeutically effective doses is limited by adverse effects. 
Studies in knockout mice have suggested that PDE4D is the 
main isoform associated with emesis (Robichaud et al 2002), 
while PDE4B appears to be the main isoform responsible 
for mediating TNFα release (Jin and Conti 2002). This has 
led to the suggestion that PDE4B inhibitors may have anti-
inﬂ  ammatory properties in COPD which will not be limited 
by adverse effects. Alternative strategies to improve the 
therapeutic ratio of PDE4 inhibitors are to target isoforms 
that appear to be only expressed as part of the inﬂ  ammatory 
process in COPD, such as PDE4A4, or to develop dual 
speciﬁ  city inhibitors which inhibit PDE4 and either PDE1, 
PDE3, or PDE7 (Giembycz 2005).
A number of molecules are currently under investigation 
as clinically useful PDE4 inhibitors (Table 1) and some of 
these also have speciﬁ  city for other PDE isozymes. The 
clinical development of many compounds has been discon-
tinued because of lack of efﬁ  cacy or because of unacceptable 
side effects. Most have been assessed as oral therapy but 
Arofylline (LAS-31025) was trialled as an inhaled therapy 
(Newman et al 1997) although its development was halted 
in Phase III because of undesirable side effects. Some com-
pounds, such as L-826,141 from Merck, have shown that 
it may be possible to differentially inhibit PDE4 subtypes 
(IC50 = 0.26 to 2.4 nM for catalytic domain activity of 
PDE4A, PDEB, PDEC, and PDED (Claveau et al 2004) 
and such properties offer exciting opportunities to reﬁ  ne the 
effectiveness and clinical utility of PDE4 inhibitors.
PDE1 isoforms
PDE1 was ﬁ  rst identiﬁ  ed in rat brain tissue in 1970 (Kakiuchi 
and Yamazaki 1970). It is almost exclusively activated 
by changes in intracellular Ca2+ concentrations and it was 
shown that the Ca2+ sensitivity of the enzyme was enhanced 
by a protein factor subsequently called calmodulin (CaM) 
(Teo and Wang 1973). An increase in intracellular calcium 
concentrations often leads to a fall in cAMP levels. In some 
cells this is mediated by Ca2+-inhibitable adenylyl cyclases 
(AC5 and AC6), while in others it is due to PDE1.
The PDE1 subfamily is as diverse as the PDE4 subfamily 
and is encoded by three genes giving the isoforms PDE1A, 
PDE1B, and PDE1C. These differ in their substrate 
speciﬁ  city, regulatory properties and tissue distribution. 
PDE1A and PDE1B preferentially hydrolyze cGMP, 
whereas PDE1C degrades both cAMP and cGMP with high 
afﬁ  nity.
The PDE1A gene has been located on chromosome 
2q32 and currently nine splice variants have been described 
(Michibata et al 2001). These include 3 splice variants at 
the N-terminal end and 3 at the C-terminal end. Different 
N-terminal domains are associated with different tissue 
distributions. PDE1A1, PDE1A4, and PDE1A8 have the N2 
terminal sequence and are widely expressed in lung and other 
tissues, whilst PDE1A5, PDE1A6, and PDE1A9 have the N1 
sequence and are expressed in brain tissue and PDE1A10 and 
PDE1A11 which have the N3 sequence are expressed in testis 
(Michibata et al 2001). Differences in the C-terminal domain 
may affect the level of expression within tissues.
The PDE1B gene is located on chromosome 12q13. 
Two splice variants, PDE1B1 and PDE1B2, have been 
described (Fidock et al 2002). PDE1B expression is lower 
than other members of the PDE1 family. Neither form is 
found in lung tissue. Selective upregulation of PDE1B2 has 
been described on monocyte to macrophage differentiation 
(Bender et al 2005) and appears to have a role in determin-
ing the phenotype of the macrophage (Bender and Beavo 
2006). PDE1B also appears to play an important role in 
T-cell activation and survival (Jiang et al 1996; Kanda and 
Watanabe 2001).
The PDE1C gene is located on chromosome 7p14.3. 
Five splice variants with differing tissue distributions have 
been described in mice (Yan et al 1996) and it appears that 
there may be at least as many human variants (Bingham 
et al 2006). PDE1C is the main cAMP hydrolytic activity in 
proliferating smooth muscle cells in the presence of Ca2+. It is 
localized to the nucleus and appears to be involved in regu-
lating smooth muscle proliferation (Rybalkin et al 2002a; 
Dolci et al 2006). As well as regulating smooth muscle 
tone, cyclic nucleotides inhibit smooth muscle proliferation 
(Koyama et al 2001)
PDE1 exists as a dimmer. In bovine brain, PDE1B1 
and PDE1A2 homodimers have been puriﬁ  ed but there is 
also evidence for the presence of a heterodimer containing 
PDE1B1 and PDE1A2. The relationship between struc-
ture and function of the PDE1 isoforms is complex. Some 
isoforms exhibit almost identical kinetic properties but are 
differentially regulated by CaM and Ca2+, whilst others show International Journal of COPD 2008:3(4) 551
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different kinetic properties (Sharma et al 2006). Despite the 
diversity of the isoforms, the overall structure of all PDE1s is 
similar. They all contain the common PDE catalytic domain 
and in addition they all have two CaM binding sites and a 
conserved inhibitory domain which holds the enzyme in a 
less active state in the absence of Ca2+ and CaM. For at least 
some of the isoforms it appears that CaM binding to just one 
of the CaM binding sites is sufﬁ  cient to activate the enzyme 
(Sonnenburg et al 1995). It has been suggested that the 
presence of the second CaM binding sites may be important 
for intracellular targeting. As well as the CaM binding sites 
shared with other PDE1 isoforms, a PDE1 isoform puriﬁ  ed 
from rabbit and bovine lung tissue also contains calmodu-
lin as an integral subunit. Differences in the N-terminal 
domain can have profound inﬂ  uences on the regulation of 
the enzyme. PDE1A1 and PDE1A2 differ in only a single 
segment of 34 residues (Novack et al 1991), yet CaM is a 
10-fold more potent activator of PDE1A1 than PDE1A2 
(Sonnenburg et al 1995). PDE1 isoforms are also regulated 
by phosphorylation. There are complex interactions between 
phosphorylation and the effects of CaM. For example, Ca2+/
CaM can block phosphorylation of PDE1A2 and PDE1A1, 
whilst Ca2+/CaM stimulate phosphorylation of PDE1B1. 
Furthermore Ca2+/CaM can reverse phosphorylation of PDE1 
isozymes through activation of CaM-dependent protein 
phosphatase (calcineurin) (Sharma et al 2006). A number 
of different phosphorylases are involved in the regulation of 
PDE1. PDE1A1 and PDE1A2 are phosphorylated by cAMP-
dependent protein kinase (Sharma 1991; Sharma and Wang, 
1985, Sharma et al 2002), while PDE1B1 is a substrate of 
CaM-dependent protein kinase II (Sharma and Wang 1986). 
Phosphorylation of PDE1 also changes the afﬁ  nity of the 
isozymes for CaM. Thus, overall, the effect of CaM on 
PDE1 is complex since CaM activation is partly reversed by 
CaM-dependent phosphorylation, which, in turn, is opposed 
by the action of CaM-dependent phosphatase. In vivo these 
events may be temporally separated (Kakkar et al 1999).
Several drugs inhibit PDE1 including ginsenoides and 
selegeline (Sharma and Kalra 1993; Kakkar et al 1996). 
Amantadine selectively inhibits some but not all isoforms. 
It inhibits PDE1A1 but not PDE1A2 or PDE1B1 (Kakkar 
et al 1997) and it is thought that dihydropyridine calcium 
antagonists such as felodipine and nicardipine may also 
inhibit PDE1 isozymes (Sharma et al 1997). From a pulmo-
nary perspective it has been shown that inhibition of PDE1 by 
vinpocetine augmented the pulmonary vasodilator response 
to nitric oxide in lambs (Evgenov et al 2006) suggesting that 
PDE1 inhibition may have a role in treatment of pulmonary 
hypertension and given the role of PDE1 in smooth muscle 
proliferation it may have disease modifying potential.
PDE3 isoforms
Members of the PDE3 family are characterized by hydrophobic 
N-terminal membrane association domains. They exhibit high 
afﬁ  nity for both cAMP and cGMP but the Vmax for cGMP 
hydrolysis is 4–10 times higher (Degerman et al 1997). PDE3 
differs from PDE4 in that it has high afﬁ  nity for both cAMP 
and cGMP so that these substrates are mutually competitive 
and thus PDE3 hydrolysis of cAMP can be inhibited by cGMP. 
PDE4 is not inhibited by cGMP and thus originally PDE3 
was called cGMP-inhibited PDE to distinguish it from PDE4. 
cGMP inhibition of PDE3 may be physiologically relevant to 
the elevation of cAMP levels in a variety of cells including 
human myocytes, where nitric oxide induced relaxation may 
be mediated by activation of guanylyl cyclase, elevation of 
intracellular cGMP levels and inhibition of PDE3 leading to 
elevated cAMP levels (Kirstein et al 1995). PDE3 is clini-
cally signiﬁ  cant because of its role in regulating vascular and 
cardiac smooth muscle as well as platelet aggregation.
Two genes encoding PDE3 have been isolated (Beavo 
et al 1994). PDE3A is located on chromosome 12p12 and 
PDE3B is located on chromosome 11p15.1 (Miki et al 1996; 
Kasuya et al 2000). PDE3A is found in myocardium, arterial, 
venous, bronchial, and gastrointestinal smooth muscle, 
while PDE3B is found in adipose tissue (Reinhardt et al 
1995). In the lung, PDE3 activity is prominent in alveolar 
macrophages, endothelial cells, platelets, and airway smooth 
muscle cells. Three isoforms of PD3A have been identiﬁ  ed in 
human myocardium. They are designated PDE3A-136, -118 
and -94 because of the differing lengths of their N-terminal 
domains and appear to be generated by a combination of alter-
native transcriptional and post-transcriptional processing. 
PDE3a-136 appears to be located exclusively in microsomal 
fractions whilst the other two isoforms are present in both 
cytosolic and microsomal fractions (Smith et al 1993). The 
isoforms have different regulatory properties, as result 
of loss of regulatory sites, and thus their different subcellular 
locations enables differential spatial regulation of cAMP 
levels (Hambleton et al 2005).
The structural organization of PDE3A and PDE3B 
proteins is similar. The catalytic domain of PDE3 contains 
a 44 amino acid insert not found in other PDEs and which 
differs between the isoforms. This insert interrupts the ﬁ  rst 
of the Zn2+ binding domains present in the catalytic domains 
but whether it is involved in its interaction with substrates or 
inhibitors remains unclear. There are signiﬁ  cant differences International Journal of COPD 2008:3(4) 552
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in the amino acid sequence of the N-terminal regions of 
PDE3A and PDE3B, but they both contain two hydrophobic 
regions involved in intracellular targeting termed N-terminal 
hydrophobic regions (“NHRs”) and sites for phosphoryla-
tion and activation by PK-B (Degerman et al 1997). NHR1 
contains transmembrane helices, whereas NHR2 appears to 
be involved in the binding of PDE3 to other currently uniden-
tiﬁ  ed proteins. The three regulatory phosphorylation sites 
which are phosphorylated by PK-B and PK-A lie between 
NHR1 and NHR2 (Rascon et al 1994; Kitamura et al 1999; 
Rondinone et al 2000). Phosphorylation of PDE3 is important 
in activating PDE3 in response to a variety of extracellular 
signals in cardiac, vascular and airway smooth muscle, as 
well as a number of other cells, including adipocytes and 
platelets (Degerman et al 1997). It has recently been shown 
that phosphorylation allows the binding of 14-3-3 proteins to 
PDE3 (Figure 2) (Pozuelo Rubio et al 2005). These proteins 
bind to speciﬁ  c phosphorylated sites on diverse target pro-
teins, and appear to either force conformational changes that 
cannot be induced by phosphorylation alone or act as double 
ended “adapters” induce interactions between their targets 
and other molecules. Their importance as integrators of the 
speciﬁ  city and strength of signaling is just being recognized 
(Mackintosh 2004; Pozuelo Rubio et al 2004).
PDE3 can be inhibited by a number of drugs, including 
cilostamide, enoximone, and lixazinone. PDE3 inhibitors 
enhance myocardial contractility and induce vascular and 
airway smooth muscle relaxation (Leeman et al 1987; 
Myou et al 1999; Fujimura et al 1995). Siguazodan, a 
PDE3 inhibitor, potentiated relaxation induced by rolipram 
suggesting an interaction between PDE3 inhibition and PDE4 
inhibition (Torphy et al 1993). Similarly, although PDE3 
Table 2 PDE4 inhibitors in current and discontinued clinical development
PDE4 inhibitor Company Status Reference
Cilomilast GlaxoSmithKline Phase III (Christensen et al 1998)
Roﬂ  umilast Altana Phase III (Hatzelmann and Schudt 2001)
BAY 19–8004 Bayer plc Phase II (Grootendorst et al 2003)
AWD 12–281 Elbion AG/GlaxoSmithKline Phase II (Gutke et al 2005)
Cipamfylline, BRL-61063 Leo Pharmaceuticals Phase II (Kucharekova et al 2003)
Mesopram, SH-636 Schering AG Phase II (Loher et al 2003)
CC-10004 Celgene Phase II (Baumer et al 2007)
Oglemilast, GRC-3886 Glenmark Phase II (Enefer 2005)
Tetomilast, OPC-6535 Otsuka Phase II (Chihiro et al 1995)
Toﬁ  milast, CP-325366 Pﬁ  zer Phase II (Duplantier et al 2007)
ONO-6126 Ono Pharmaceuticals Phase I (Furuie et al 2003)
CI-1044 Pﬁ  zer Phase I (Ouagued et al 2005)
HT-0712 Inﬂ  azyme/Helicon Phase I (MacDonald et al 2007)
Ibudilast Merck-Frosst Phase I (Huang et al 2006)
MK-0873 Merck Phase I (Boot et al 2008)
Arofylline, LAS-31025 Almirall Discont (Beleta et al 1996)
CI-1018 Pﬁ  zer Discont (Burnouf et al 2000)
T-2585 Tanabe (Ukita et al 1999)
YM-976 Yamanouchi Discont (Aoki et al 2000)
V-11294A Napp Discont (Gale et al 2002)
Piclamilast, RP-73401 Rhone-Poulenc-Rorer Discont (Chen et al 2004)
Atizoram, CP-80633 Pﬁ  zer Discont (Wright et al 1997)
Filaminast, WAY-PDA-641 Wyeth-Ayerst Discont (Heaslip et al 1994)
SCH 351591 Schering-Plough Discont (Billah et al 2002)
IC-485 ICOS Corporation Discont
Lirimilast, BAY-19-8004 Bayer Discont (Sturton and Fitzgerald 2002)
D-4418 Celltech/Schering-Plough Discont (Buckley et al 2000)
CDP-840 Celltech/Merck-Frosst Discont (Alexander et al 2002)
L-826,141 Celltech/Merck-Frosst Discont (Claveau et al 2004)
Discont, – Development discontinued.International Journal of COPD 2008:3(4) 553
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inhibitors do not appear to have direct anti-inﬂ  ammatory 
actions, they appear to augment the anti-inﬂ  ammatory actions 
of PDE4 inhibitors (Robicsek et al 1991; Schudt et al 1995; 
Giembycz et al 1996).
PDE5 isoforms
PDE5 has become of considerable clinical interest as it is 
the target of sildenaﬁ  l, the treatment for erectile dysfunction. 
PDE5 was ﬁ  rst identiﬁ  ed in rat lung tissue (Lincoln et al 
1976) and its enzyme activity has subsequently been identi-
ﬁ  ed in many other tissues. The enzyme has been puriﬁ  ed and 
cloned (Francis et al 1980; Thomas et al 1990a; McAllister-
Lucas et al 1993) and the human gene identiﬁ  ed on chromo-
some 4q26 (Loughney et al 1998; Yanaka et al 1998). It has 
subsequently been shown that there are three splice variants 
designated PDE5A1, PDE5A2, and PDE5A3 (Kotera et al 
1998; Loughney et al 1998; Lin et al 2000). PDE5A1 and A2 
isoforms are expressed in a wide variety of tissues, includ-
ing lung, heart, skeletal muscle, brain, kidney, and liver, but 
the A3 isoform is conﬁ  ned to tissues with a smooth muscle 
or cardiac muscle component (Lin et al 2000). Whether 
the splice variants affect sub-cellular localization of PDE5 
activity is not yet known, but there are preliminary reports 
that PDE5 activity is associated with cytoplasmic vesicles 
and in the centrosomal area of human myometrial cells 
(Dolci et al 2006).
PDE5 exists as a homodimer, and as well as the conserved 
catalytic site, it contains highly cGMP-speciﬁ  c allosteric 
(non-catalytic) cGMP-binding sites and a phosphorylation 
site in the N-terminal domain (Corbin and Francis 1999). The 
protein sequence of the allosteric binding sites is conserved 
across PDE2, PDE5, PDE6, and PDE10 and these tandem 
homologous repeats of 110 amino acids each in the regulatory 
domain are termed GAF domains (a and b) because of their 
presence in cGMP-binding cyclic nucleotide PDEs, Ana-
baena adenylyl cyclase, and the bacterial transcription factor 
FhlA (Thomas et al 1990a; McAllister-Lucas et al 1995; 
Aravind and Ponting 1997). Allosteric binding of cGMP to 
PDE5 regulatory domain increases afﬁ  nity of the catalytic 
site for cGMP, thereby stimulating the rate of cGMP hydro-
lysis (Thomas et al 1990b; Mullershausen et al 2001; Okada 
and Asakawa 2002; Corbin et al 2003; Rybalkin et al 2003). 
cGMP binding to the regulatory domain also stimulates 
phosphorylation of PDE5 by cGMP-dependent protein kinase 
(Thomas et al 1990b; Wyatt et al 1998; Mullershausen et al 
2001; Murthy 2001; Rybalkin et al 2002b). cGMP binding 
to these sites must be preceded by occupation of the catalytic 
site by cGMP (Francis et al 1980; Thomas et al 1990b) and it 
appears that cGMP binding to the regulatory domain produces 
a conformational change in PDE5 that exposes Ser-92 allow-
ing phosphorylation which increases afﬁ  nity of the regulatory 
domain for cGMP and increases catalytic activity as well 
(Corbin et al 2000). Thus, when intracellular cGMP levels 
rise, cGMP breakdown is enhanced both by increased activity 
at the catalytic site, followed by enhanced cGMP binding at 
the allosteric sites, leading to increased enzymatic activity 
as a result of phosphorylation. Classical PDE5 inhibitors and 
selected cyclic nucleotide analogs compete with cGMP at 
the catalytic site but do not interact with the cGMP-binding 
allosteric sites (Blount et al 2004).
As a major regulator of cGMP in smooth muscle cells, 
PDE5 controls the cGMP-dependent protein kinase (PKG) 
regulation of smooth muscle tone by nitric oxide (NO), 
atrial natriuretic peptide (ANP), and other endogenous 
vasodilators, especially under conditions of low calcium. 
PKG phosphorylates the regulatory myosin-binding subunit 
of myosin phosphatase (Surks et al 1999), calcium-activated 
maxi K+ (BKCa) channels (Fukao et al 1999), and IRAG (IP3 
receptor associated cGMP kinase substrate)(Schlossmann 
et al 2000), leading to a reduction of intracellular Ca2+ 
concentration or reduction in sensitivity to Ca2+ and thereby 
decreased smooth muscle tone (Schlossmann et al 2003).
PDE7 isoforms
PDE7 was ﬁ  rst identiﬁ  ed as part of a human DNA screening 
programme (Michaeli et al 1993). It is a high afﬁ  nity cAMP-
speciﬁ  c PDE and it is insensitive to potent selective inhibitors 
of other PDE families such as rolipram and milrinone. Two 
genes encoding PDE7 have been identiﬁ  ed in humans (Gardner 
et al 2000 Hetman et al 2000; Sasaki et al 2000). PDE7A is on 
chromosome 8q13 (Han et al 1998) and PDE7B is on chromo-
some 6q23–q24. Three splice variants of PDE7A have been 
described (PDE7A1, PDE7A2, and PDE7A3) but in humans, 
unlike mice, only one form of PDE7B has been described. 
Compared with PDE7A1, PDE7A2 has an additional 20 amino 
acid hydrophobic region in the N-terminal domain which is 
thought to be responsible for membrane tethering.
mRNA for PDE7A1 and PDE7A2 can be detected in 
airway and vascular smooth muscle cells, airway epithelial 
cells, CD4 and CD8 T-cells, neutrophils, macrophages and 
monocytes, while PDE7A3 is expressed in T-cells (Bloom 
and Beavo 1996; Han et al 1997; Glavas et al 2001; Smith 
et al 2003). It appears that PDE7A1 expression is low in 
naïve T cells but increases on activation by CD3 X CD28 
costimulation (Li et al 1999). PDE7B is expressed predomi-
nantly in the brain but is also found in a number of other International Journal of COPD 2008:3(4) 554
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tissues including liver, heart, thyroid and skeletal muscle 
but not leukocytes (Gardner et al 2000; Hetman et al 2000; 
Sasaki et al 2000). Despite the expression of PDE7A2 
mRNA in smooth muscle and leukocytes no protein could 
be detected in these cells, suggesting that if expressed at all, 
the amount of PDE7A2 present is very low and the amount 
of PDE7A1 protein is greater in T-cells than in airway and 
vascular smooth muscle cells (Smith et al 2003). Alternative 
splicing of PDE7A determines the subcellular localization of 
its protein products without affecting their kinetic properties. 
The hydrophobic N-terminus of PDE7A2 leads to membrane 
association (Han et al 1997), while PDE7A1 appears to be 
associated with the Golgi in T cells through associations 
with the AKAP scaffolding protein myeloid translocation 
gene (MTG) (Figure 2) (Asirvatham et al 2004), which also 
targets PKA to the Golgi in T cells (Schillace et al 2002). 
The N-terminal domain of PDE7A1 also contains two copies 
of a PKA pseudosubstrate site which bind to and inhibit the 
activity of the catalytic subunit of PKA (Han et al 2006). 
Thus, in addition to cAMP hydrolysis, PDE7A1 can termi-
nate cAMP signaling by direct interaction with the catalytic 
subunit of PKA.
Given the distribution of PDE7A1 in pro-inﬂ  ammatory and 
airway cells there has been considerable interest in whether 
inhibition of PDE7A may be anti-inﬂ  ammatory and of thera-
peutic beneﬁ  t in COPD. However, there is conﬂ  icting evidence 
in mice about the effects of inhibiting PDE7A on T cell prolif-
eration and IL-2 production (Li et al 1999; Yang et al 2003). 
This may reﬂ  ect the methods used to inhibit PDE7A activity 
which used different molecular genetic techniques to block 
PDE7A activity. A few selective inhibitors of PDE7 have now 
been identiﬁ  ed (Giembycz 2005) and using these it is becoming 
clear that inhibition of PDE7A can regulate proinﬂ  ammatory 
and immune cell function when used in associated with PDE4 
inhibitors. For example, although inhibition of PDE7A with 
BRL 50481 does not itself affect T cell proliferation or TNF-α 
production by macrophages, it does augment the effects of 
rolipram on these cells (Smith et al 2004).
Clinical effects of PDE inhibitors 
in COPD
As a result of greater knowledge about isoforms of 
PDE and their role in regulating inﬂ  ammatory cells and 
airway and vascular smooth muscle there has been consider-
able interest in the clinical effects of PDE inhibitors in patients 
with COPD. Most interest has centered on inhibition of PDE4 
and three drugs have reached phase III clinical trials in patients 
with COPD: rolipram, cilomilast, and roﬂ  umilast.
Unfortunately the use of rolipram was limited by 
signiﬁ  cant side effects: particularly nausea, vomiting and 
gastric acid secretion (Horowski and Sastre-Y-Hernandez 
1985) due to inhibition of PDE4 in the CNS and gastric 
parietal glands. These ﬁ  ndings led to the development of the 
second generation PDE4 inhibitors roﬂ  umilast and cilomilast 
which have better therapeutic ratios (Torphy et al 1999).
Roﬂ  umilast has proven anti-inﬂ  ammatory properties 
in vitro and in animal models (Bundschuh et al 2001; 
Hatzelmann and Schudt 2001). Preliminary clinical data 
suggested that roﬂ  umilast could improve lung function while 
being well tolerated in patients with COPD when given orally 
once daily (Lipworth 2005) and a 24-week clinical trial 
showed that it improved lung function and reduced exacerba-
tions compared with placebo (Rabe et al 2005). A subsequent, 
year-long trial has again shown that it improved lung func-
tion, but in this study there was no effect on health status or 
exacerbation rates (Calverley et al 2007).
Cilomilast is another second generation PDE4 inhibitor 
which shows anti-inﬂ  ammatory effects in both pre-clinical and 
clinical studies (Barnette et al 1998; Griswold et al 1998; Torphy 
et al 1999; Gamble et al 2003; Proﬁ  ta et al 2003). Bronchial 
biopsies, taken from COPD patients, randomized to receive 
either cilomilast orally or placebo for 12 weeks showed that 
cilomilast signiﬁ  cantly reduced the number of inﬁ  ltrating tissue 
CD8+ T cells and CD68+ macrophages by 48% (  p  0.01) 
and 47% ( p  0.001), respectively (Gamble et al 2003) and a 
clinical trial in patients with COPD showed that it improved lung 
function and health status compared with placebo and reduced 
exacerbations over 24 weeks (Rennard et al 2006)
Both cilomilast and roﬂ  umilast cause nausea, diarrhea, 
headache, abdominal pain and dizziness. GI side effects 
appear more common in patients taking cilomilast than 
roﬂ  umilast (Rennard et al 2006; Rabe et al 2005; Calverley 
et al 2007). In preclinical trials in rats and dogs PDE4 
inhibitors have been associated with the development of 
arteritis/periarteritis (Giembycz 2005). These species appear 
particularly susceptible to this toxic effect but some PDE4 
inhibitors may also cause this effect in primates: arteritis 
has been reported to have been produced in cynomolgus 
monkeys (Losco et al 2004) and Merck discontinued the 
development of a PDE4 inhibitor because of the occurrence 
of colitis (Giembycz 2005). To date, no PDE4 inhibitor has 
received a license from the FDA or EMEA.
Future directions
The side effects of PDE4 inhibitors reﬂ  ect the ubiquitous 
distribution of PDE4 isozymes and their importance in a International Journal of COPD 2008:3(4) 555
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wide variety of cellular processes. The therapeutic ratio of 
PDE4 inhibitors may be improved by using speciﬁ  c inhibitors 
targeting those isozymes in airway smooth muscle or inﬂ  am-
matory cells or which are relatively inactive against PDE4C, 
the isoform that predominates in the CNS. Developing 
such inhibitors presents a considerable challenge given the 
conserved nature of the catalytic site and the similarity of 
the overall sequence of the four subtypes. Nevertheless, 
dual PDE4A/D and speciﬁ  c PDE4D inhibitors have been 
developed and tested in in vitro models (Muller et al 1996; 
Manning et al 1999; Giovannoni et al 2007) but they have 
not yet been assessed in clinical trials.
An alternative strategy to improve the tolerability of 
PDE4 inhibitors is to develop dual speciﬁ  city inhibitors 
that inhibit both PDE4 and either PDE1, PDE3 or PDE7. 
In this way the anti-inﬂ  ammatory properties may be aug-
mented whilst reducing PDE4 related side-effects in other 
organs. Although inhibitors of PDE3 have little intrinsic 
anti-inﬂ  ammatory action they do appear to augment the 
anti-inﬂ  ammatory properties of PDE4 inhibitors (Robicsek 
et al 1991; Giembycz et al 1996; Schudt et al 1995). Simi-
larly, there is some in vitro evidence that inhibition of PDE7 
may augment the effects of PDE4 inhibition (Smith et al 
2004), although PDE7A inhibitors have little or no anti-
inﬂ  ammatory properties themselves (Giembycz 2005). Dual 
speciﬁ  city PDE inhibitors have been developed, but none 
of have reached phase III trials and there are still concerns 
about the toxic effects of inhibiting members of other PDE 
families (Giembycz 2005).
Although there are no selective PDE1 inhibitors 
available for clinical use at present, PDE1 inhibition offers 
theoretical anti-inﬂ  ammatory beneﬁ  ts in COPD through 
inhibition of T-cell activation and inducing apoptosis, and 
prevention of the development of pulmonary hypertension 
as a result of augmenting pulmonary vasodilatation and 
inhibiting vascular smooth muscle proliferation. Thus, dual 
speciﬁ  city PDE inhibitors that inhibit PDE1 may offer greater 
anti-inﬂ  ammatory potential if combined with anti-PDE4 
activity, or enhanced and sustained effects on pulmonary 
hypertension if combined with anti-PDE5 activity.
Given their tissue distribution, in particular their 
presence in pulmonary and vascular smooth muscle, it is 
possible that inhibition of PDE3 and PDE5 could be of 
beneﬁ  t in patients with COPD. Selective PDE3 inhibitors 
promote bronchodilatation in humans (Leeman et al 1987; 
Fujimura et al 1995; Myou et al 1999) and inhibition of 
PDE5 with sildenaﬁ  l reduces pulmonary vascular resistance 
in subjects with hypoxic-induced pulmonary hypertension 
and in patients with severe pulmonary hypertension (Zhao 
et al 2001; Ghofrani et al 2004; Sastry et al 2004). There is 
also some preliminary evidence that PDE5 inhibitors may 
also have anti-inﬂ  ammatory properties similar to the PDE4 
inhibitors. Sildenaﬁ  l pre-treatment inhibited LPS-induced 
airway hyperreactivity, leukocyte inﬂ  ux, and NO genera-
tion in a guinea pig model of airways disease as a result of 
inhibition of PDE5 rather than via effects on NO synthase 
(Toward et al 2004) and a single case report of 2 patients with 
COPD taking sildenaﬁ  l for erectile dysfunction, described 
improvements in FEV1 (Charan 2001). Further randomized 
studies are required to investigate this effect further.
Conclusion
There are currently nearly 100 members of the PDE super-
family divided into 11 families, with multiple isoforms in 
most families based on different genes and alternate splicing 
of gene products. PDEs control the duration and localization 
of intracellular cyclic nucleotide signaling and mediate inter-
actions with other signaling cascades including the MAP 
kinase and Ca2+ pathways. The activity of PDEs is regulated 
by phosphorylation and interaction with other signaling mol-
ecules, some of which are assembled into macromolecular 
complexes with PDE by scaffolding proteins. Inhibition of 
cyclic nucleotide hydrolysis leads to elevation of their levels 
with consequent effects on cellular proliferation, smooth 
muscle relaxation and inhibition of inﬂ  ammatory cells. 
Inhibition of PDE4 is currently the most tested strategy for 
patients with COPD but in clinical practice the beneﬁ  ts have 
been modest and its use has been limited by adverse effects. 
As understanding of the roles of PDE4 isoforms and other 
members of the PDE superfamily grows, these problems may 
be overcome by using isoform speciﬁ  c inhibitors as well as 
dual speciﬁ  city inhibitors.
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AC, adenyl cyclase; AC5, Ca2+-inhibitable adenylyl cyclase 
5; AC6, Ca2+-inhibitable adenylyl cyclase 6; AKAP, 
A-kinase anchoring proteins; ANP, atrial natriuretic 
peptide; BKCa, calcium-activated maxi K+ channels; CaM, 
calmodulin; cAMP, adenosine 3′5′-cyclic monophosphate; 
cGMP, guanosine 3′5′-cyclic monophosphate; EPAC, GTP-
exchange protein; ERK5, extracellular signal regulated 
kinase; GAF, cGMP binding domains; GPCRs, G-protein 
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pocket; HPDE4, PDE4 high afﬁ  nity rolipram binding site; 
IL-2, interleukin 2; IL-8, interleukin 8; IL-10, interleukin 
10; IRAG, IP3 receptor associated cGMP kinase substrate; 
L region, catalytic region lid region; LHRH, luteinizing 
hormone releasing hormone; LPDE4, PDE4 low afﬁ  nity 
rolipram binding site; M site, catalytic region metal-binding 
site; MTG, AKAP scaffolding protein myeloid translocation 
gene; NHRs, N-terminal hydrophobic regions; NO, nitric 
oxide; PDEs, phospodiesterases; PKA, protein kinase A; 
Q pocket, catalytic region core pocket; TGF-β, transforming 
growth factor β; TNF-α, tumour necrosis factor α; UCR1, 
upstream conserved region 1; UCR2, upstream conserved 
region 2; XAP2, hepatitis B virus X-associated protein 2.
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